Analytical Data
-
基因名
VEGF110
-
简介
Vascular Endothelial Growth Factor A (VEGF-A) is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF110 Protein, Human (HEK293) is the recombinant human-derived VEGF110 protein, expressed by HEK293, with tag free.
- Application
-
别名
VEGF; VEGFA; L-VEGF; N-VEGF; VPF; MVCD1
-
种属
Human
-
表达系统
HEK293
-
标签
Tag Free
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P15692-9
-
表达区间
A27-R136
-
蛋白长度
Partial
-
分子量
13 kDa & 17-23 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular Endothelial Growth Factor (VEGF) plays a crucial role in angiogenesis, the process by which new blood vessels form from existing ones. Abnormal VEGF expression is implicated in various diseases, including cancer, diabetic retinopathy, and age-related macular degeneration. The VEGF110 recombinant protein, a specific isoform of VEGF, has garnered attention due to its unique properties that enhance endothelial cell proliferation and migration, making it a potential therapeutic target. Research into VEGF110 focuses on its structural characteristics, signaling pathways, and interactions with specific receptors, contributing to a deeper understanding of angiogenic mechanisms. Moreover, studies are exploring its potential utility in regenerative medicine, tissue engineering, and as an adjunct therapy for ischemic diseases. By elucidating the functional aspects of VEGF110, researchers aim to harness its angiogenic capabilities to develop innovative treatments that can effectively manage various pathologies linked to aberrant vessel growth and function. Overall, the investigation of VEGF110 not only provides insights into fundamental biological processes but also opens avenues for developing targeted therapies that utilize its pro-angiogenic properties.
